Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
64 results about "CD70" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CD70 (Cluster of Differentiation 70) is a ligand for CD27.
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ActiveUS7662387B2Prevent relapseAntibacterial agentsNervous disorderImmunosuppressive drugCytotoxicity
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Owner:SEAGEN INC
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ActiveUS20060233794A1Prevent relapseAntibacterial agentsNervous disorderDrug conjugationAntiendomysial antibodies
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Owner:SEAGEN INC
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
Owner:SEAGEN INC
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
InactiveUS20080025989A1Prevent relapseCompounds screening/testingAntibody ingredientsCytotoxicityAnti-CEA Antibody
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Owner:SEATTLE GENETICS INC
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Owner:SEAGEN INC
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
InactiveUS20130323214A1Reducing and preventing tumorNervous disorderPeptide/protein ingredientsCancer cellT cell receptor complex
The present invention concerns methods and compositions related to T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. In aspects of the invention, T cells that are CD70-specific are employed. In particular aspects, there are T cells expressing a novel molecule that comprises the full-length CD70 receptor (CD27) fused to the zeta signaling domain of the T-cell receptor complex. Such T cells recognized CD70-positive tumor cells and have cytolytic activity against CD70-positive cancer cells.
Owner:BAYLOR COLLEGE OF MEDICINE
Anti-cd70 antibody and its use for the treatment of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
Owner:SEATTLE GENETICS INC
Treatment of psoriatic arthritis with Anti-cd70 antibody
InactiveUS20100129362A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCD70Antibody
Owner:SEATTLE GENETICS INC
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
Owner:SEAGEN INC
CD70 inhibition for the treatment and prevention of inflammatory bowel disease
ActiveUS20050191299A1Reduce and eliminate inflammatory conditionGastrointestinal cellsDigestive systemInflammatory bowel diseaseCD70
Substantially purified populations of APCLP cells capable of expressing CD70 are described. Also described are methods for the treatment of certain diseases and medical conditions of the gastrointestinal tract, such as inflammatory bowel disease, by utilizing inhibitors of CD70 activity.
Owner:CENT FOR BLOOD RES
Anti-CD70 antibody and its use for the treatment of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
Owner:SEATTLE GENETICS INC
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
Owner:SEAGEN INC
Anti-CD70 Antibody And Its Use For The Treatment And Prevention Of Cancer And Immune Disorders
ActiveUS20090232806A1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCancer preventionCD70
Owner:SEAGEN INC
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
ActiveUS20180201901A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorsAntigens present
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Owner:CELLECTIS SA
Detection and treatment of pancreatic, ovarian and other cancers
ActiveUS9120854B2Polypeptide with localisation/targeting motifMicrobiological testing/measurementOncologyOvarian cancer
Owner:SEAGEN INC
Anti CD70 CAR-T cell and preparation method and application thereof
ActiveCN110592023AIncreased specificity of killingEfficient tumor killing activityAntibody mimetics/scaffoldsMammal material medical ingredientsCD8CD70
The present invention belongs to the fields of molecular biology and cell biology, and particularly relates to a CAR-T cell that specifically recognizes CD70 and a preparation method of the CAR-T cell. SCFV (Anti CD70)-CD8<TM>-4-1BB-CD3[zeta] molecules are expressed in T cells. A CD70 antibody is used for construction of CAR-T cells, CD70 molecules are used as a target antigen, and when the constructed CAR-T cells are in contact with tumor cells expressing the CD70 molecules, distance is pulled closest to increase T cell kill specificity. The prepared Anti-CD70 CAR-T cells has more efficient tumor-killing activity and can be used to prepare tumor drugs with high expression of the CD70 molecules.
Owner:ZHEJIANG BLUE SHIELD PHARM CO LTD
Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and / or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and / or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.
Owner:VRIJE UNIV BRUSSEL
Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
The present invention relates to compositions and methods for diagnosing, monitoring and / or treating an autoimmune or chronic inflammatory disease. In particular, the present invention provides methods for diagnosing, monitoring and treating an autoimmune disease (e.g., rheumatoid arthritis) or chronic inflammatory disease (e.g., systemic lupus erythematosus) based on detecting or altering (e.g., altering expression or methylation status of) autoimmune or chronic inflammatory disease proteins (e.g., CD70 and CD40L). The present invention also provides kits for detecting methylation status of autoimmune or chronic inflammatory disease proteins (e.g., CD70 and CD40L) and for diagnosing, monitoring and / or treating autoimmune or chronic inflammatory diseases.
Owner:USA DEPT OF VETERANS AFFAIRS +1
Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and / or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and / or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.
Owner:VRIJE UNIV BRUSSEL
Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
InactiveUS20110256121A1Avoid problemsLower IFN productionNervous disorderAntipyreticAutoimmune responsesHeart disease
The present invention relates to compositions and methods for diagnosing, monitoring and / or treating disease (e.g., autoimmune or chronic inflammatory disease, heart disease and / or stroke). In particular, the present invention provides methods for diagnosing, monitoring and treating disease based upon detecting or altering (e.g., altering expression or methylation status of) disease proteins (e.g., CD70, CD40L, and / or KIR). The present invention also provides kits for detecting methylation status of disease proteins (e.g., CD70, CD40L, and / or KIR) and for diagnosing, monitoring and / or treating diseases (e.g., autoimmune or chronic inflammatory disease, heart disease and / or stroke).
Owner:RGT UNIV OF MICHIGAN
Immunocompetent cells modified by dual chimeric antigen receptor genes based on CD19 and CD70 and application thereof
ActiveCN109880802AEnhance long-term immunityPrevent escapeImmunoglobulins against cell receptors/antigens/surface-determinantsMammal material medical ingredientsDiseaseTreatment effect
The invention relates to an immunocompetent cells modified by dual chimeric antigen receptor genes based on CD19 and CD70 and an application thereof. The dual chimeric antigen receptors include the chimeric antigen receptor CD19 and the chimeric antigen receptor CD70. The chimeric antigen receptor comprises an antigen binding domain, a transmembrane domain, a costimulatory signal conducting regionand a CD3 zeta signal conduct domain, and an inducible suicide fusion domain connected in series. The chimeric antigen receptor of the present invention specifically recognizes tumor surface antigensCD19 and CD70, compared to the use of other single chimeric antigen receptor T cell, the combination of two antigens is used to target CAR-T cells so that the treatment effect is better, CD19 escapeis differently generated, and the disease is easily relieved.
Owner:BEIJING MEIKANG JIMIAN BIOTECH CO LTD
Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
ActiveUS20140056939A1Reduced activityAvoid it happening againBacterial antigen ingredientsPeptide/protein ingredientsAntigenConstitutively active
Owner:VRIJE UNIV BRUSSEL
CD70 inhibition for the treatment and prevention of inflammatory bowel disease
Substantially purified populations of APCLP cells capable of expressing CD70 are described. Also described are methods for the treatment of certain diseases and medical conditions of the gastrointestinal tract, such as inflammatory bowel disease, by utilizing inhibitors of CD70 activity.
Owner:CENT FOR BLOOD RES
Hybridoma cell strain 6F9, antibody and application of hybridoma cell strain 6F9
ActiveCN110699327AStrong specificityHigh affinityBiological material analysisMicroorganism based processesAntigenAntiendomysial antibodies
The invention belongs to the technical field of biology, and particularly discloses a hybridoma cell strain 6F9, an anti-human CD70 monoclonal antibody generated by the hybridoma cell strain 6F9 and an application of the hybridoma cell strain 6F9. The the hybridoma cell strain 6F9 uses a biologically-active human CD70 recombinant protein as an antigen, and obtains a specific monoclonal antibody capable of binding human CD70 with high affinity at the cell level through hybridoma technology screening. The antibody has potential value in tumor immunotherapy.
Owner:ZHEJIANG BLUE SHIELD PHARM CO LTD
Application of CD4+CD70+T cell subset in preparing reagent for auxiliary diagnosis of very severe aplastic anemia
ActiveCN109187941AReduce the ratioDisease diagnosisIndividual particle analysisTreatment strategyLaboratory facility
The invention discloses an application of CD4+CD70+T cell subset in preparing reagent for auxiliary diagnosis of very severe aplastic anemia. According to the invention, the inventor finds for the first time that the proportion of CD4+CD70+T cell in the peripheral blood of AA patients is obviously reduced in A patients, especially, is most obvious in VSAA, which can be used as one of related testindices for auxiliary diagnosis of laboratory immunization of VSAA patients, and meanwhile, provides important reference data for selection of treatment strategy for VSAA patients clinically.
Owner:JINAN UNIVERSITY
Anti-CD70 Antibody Drug Conjugates
ActiveUS20150141624A1Increase doseAvoid toxicityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsToxinCD70
This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
Owner:AMBRX
Human CD70 antigen binding polypeptide
ActiveCN110804099AAvoid sourcingLow immunogenicityPolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsPharmaceutical drugAntigen binding
The invention discloses a human CD70 antigen binding polypeptide. The human CD70 antigen binding polypeptide with higher specificity and higher affinity is developed with human CD70 as a target. Compared with the prior art, the human CD70 antigen binding polypeptide (fusion protein) is prepared successfully, the polypeptide has good specificity and higher affinity and can bind human CD70 expressedon cell surfaces, and the anti-human CD70 monoclonal antigen binding polypeptide is a potential drug for tumor immunotherapy.
Owner:ZHEJIANG BLUE SHIELD PHARM CO LTD
Cell surface molecules as markers and therapeutic agents against kidney cancers
InactiveUS20050282168A1Efficient dosingGrowth inhibitionMicrobiological testing/measurementBiological material analysisClear cell renal cell carcinomaDisease cause
Human cell surface molecules CD70 and CD203c are expressed at higher levels in kidney carcinomas, particularly renal cell carcinomas and clear cell renal cell carcinomas, yet are expressed at low levels in normal kidney and other diseased kidney tissue, and at low levels in other tissues. CD70 and CD203c show specificity towards kidney carcinomas, particularly renal cell carcinomas and clear cell renal cell carcinomas and thus can be used as diagnostic markers and therapeutic targets for these diseases. In addition, antibodies or small molecules against these molecules could be used in treatments towards these diseases.
Owner:WYETH
Method for identifying senescent mesenchymal stem cells
InactiveUS20120165216A1Shorten the lengthImprove the level ofMicrobiological testing/measurementLibrary screeningMesenchymal stem cellCXCL1
The invention refers to a method for identifying senescent mesenchymal stem cells growing in in vitro culture, comprising: measuring the length of chromosome telomeres, determining the level of ploidy in the cell, detecting the presence of multipolar mitosis and determining the level of expression of the genes SCIN, AKAP9, EDN-1, CXCL1, CXCL12 and / or CD70. This method can be used for performing genetic stability studies in mesenchymal stem cell cultures, enabling identification and selection of the most stable and appropriate cells for use in cell therapy.
Owner:CENT NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC
Method for efficiently amplifying NK cells in vitro
ActiveCN111172115AIncrease lethalityHigh kill rateGenetically modified cellsNGF/TNF-superfamilyNatural Killer Cell Inhibitory ReceptorsTrophoblast
The invention provides a method for amplifying NK cells by utilizing gene modified K562 trophoblast cells. IL-21, IL-27 and CD70 genes are transfected into K562 cells through a lentivirus reprint system, so that K562 engineering cells capable of stably expressing IL-21, IL-27 and CD70 protein can be obtained; the K562 engineering cells are mixed with PBMC to perform cultivation after being inactivated, so that the NK cells can be amplified in a serum-free medium under the presence of IL-2, and the amplification multiples can be about 800-1,100; the effective purity of the NK cells can reach 91%, and the secretion volume of IFN-gamma can be five times that of the NK cells cultivated by common methods; and the killing rate of the NK cells on hepatoma carcinoma cell HepG2 can reach 88.5% under the condition that effector-target ratio is 10: 1, which is about 20% higher than that of the NK cells cultivated under normal conditions, and therefore, the NK cells cultivated by the method have stronger killing abilities.
Owner:山东省齐鲁细胞治疗工程技术有限公司 +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com